UY38605A - Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1 - Google Patents
Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1Info
- Publication number
- UY38605A UY38605A UY0001038605A UY38605A UY38605A UY 38605 A UY38605 A UY 38605A UY 0001038605 A UY0001038605 A UY 0001038605A UY 38605 A UY38605 A UY 38605A UY 38605 A UY38605 A UY 38605A
- Authority
- UY
- Uruguay
- Prior art keywords
- lingo
- pharmaceutical compositions
- antibodies
- compositions containing
- containing anti
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000003435 Optic Neuritis Diseases 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816668P | 2019-03-11 | 2019-03-11 | |
| US201962817323P | 2019-03-12 | 2019-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38605A true UY38605A (es) | 2020-09-30 |
Family
ID=70190131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038605A UY38605A (es) | 2019-03-11 | 2020-03-10 | Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220144945A1 (enExample) |
| EP (1) | EP3938395A1 (enExample) |
| JP (1) | JP2022524814A (enExample) |
| KR (1) | KR20210136063A (enExample) |
| CN (1) | CN113661179A (enExample) |
| AU (1) | AU2020234943A1 (enExample) |
| BR (1) | BR112021017644A2 (enExample) |
| CA (1) | CA3133072A1 (enExample) |
| IL (1) | IL286162A (enExample) |
| MA (1) | MA55298A (enExample) |
| MX (1) | MX2021010420A (enExample) |
| TW (1) | TW202103732A (enExample) |
| UY (1) | UY38605A (enExample) |
| WO (1) | WO2020185750A1 (enExample) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| SG44845A1 (en) | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| AU687790B2 (en) | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| ES2537015T3 (es) | 2003-03-19 | 2015-06-01 | Biogen Ma Inc. | Proteína de unión del receptor de NOGO |
| EP1776136B1 (en) | 2004-06-24 | 2012-10-03 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
| WO2018013714A1 (en) * | 2016-07-13 | 2018-01-18 | Biogen Ma Inc. | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders |
| WO2018204374A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| KR20250053967A (ko) * | 2017-08-22 | 2025-04-22 | 바이오젠 엠에이 인코포레이티드 | 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물 |
-
2020
- 2020-03-10 MX MX2021010420A patent/MX2021010420A/es unknown
- 2020-03-10 WO PCT/US2020/021842 patent/WO2020185750A1/en not_active Ceased
- 2020-03-10 AU AU2020234943A patent/AU2020234943A1/en not_active Abandoned
- 2020-03-10 EP EP20717406.1A patent/EP3938395A1/en not_active Withdrawn
- 2020-03-10 MA MA055298A patent/MA55298A/fr unknown
- 2020-03-10 UY UY0001038605A patent/UY38605A/es not_active Application Discontinuation
- 2020-03-10 JP JP2021554699A patent/JP2022524814A/ja active Pending
- 2020-03-10 CN CN202080027211.8A patent/CN113661179A/zh active Pending
- 2020-03-10 US US17/437,634 patent/US20220144945A1/en not_active Abandoned
- 2020-03-10 KR KR1020217031856A patent/KR20210136063A/ko not_active Withdrawn
- 2020-03-10 BR BR112021017644A patent/BR112021017644A2/pt not_active Application Discontinuation
- 2020-03-10 CA CA3133072A patent/CA3133072A1/en active Pending
- 2020-03-10 TW TW109107890A patent/TW202103732A/zh unknown
-
2021
- 2021-09-05 IL IL286162A patent/IL286162A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220144945A1 (en) | 2022-05-12 |
| BR112021017644A2 (pt) | 2021-11-16 |
| MA55298A (fr) | 2022-01-19 |
| CA3133072A1 (en) | 2020-09-17 |
| IL286162A (en) | 2021-10-31 |
| KR20210136063A (ko) | 2021-11-16 |
| MX2021010420A (es) | 2021-11-12 |
| AU2020234943A1 (en) | 2021-09-23 |
| WO2020185750A1 (en) | 2020-09-17 |
| EP3938395A1 (en) | 2022-01-19 |
| JP2022524814A (ja) | 2022-05-10 |
| CN113661179A (zh) | 2021-11-16 |
| TW202103732A (zh) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025003876A (es) | Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina | |
| EP4516301A3 (en) | Nitrile-containing compounds for use as medicaments | |
| EA202190983A1 (ru) | Новое антитело к с-kit | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
| UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| CO2018004968A2 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| DOP2017000047A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| UY37169A (es) | Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen | |
| DOP2021000130A (es) | Moduladores de la expresion de hsd17b13 | |
| MX2024010300A (es) | Composiciones farmaceuticas que contienen anticuerpos anti-beta-amiloides. | |
| CO2021015998A2 (es) | Materiales y métodos para modular la inmunidad mediada por células t | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| PH12021550102A1 (en) | Cardiosafe antidiabetic therapy | |
| CO2017011958A2 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
| WO2018189661A3 (en) | Methods and compounds for treating diabetes | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| MX374931B (es) | Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. | |
| UY38605A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1 | |
| AR118304A1 (es) | Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1 | |
| MY191993A (en) | Use of isolated fractions of mastic gum for treating optic neuropathy | |
| PH12021551212A1 (en) | Process for preparation of anthranilamides | |
| SA521431223B1 (ar) | Angpt2 أجسام مضادة لـ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20241111 |